Group 1 - The company, Fu'an Pharmaceutical (300194), announced on September 26 that it primarily invests in generic drugs based on its characteristics [1] - The company is also involved in the innovative drug sector through its stake in Unogen [1] - Currently, the company has no plans to invest in robot chips [1]

Group 1 - The company Fu'an Pharmaceutical (300194) announced on September 26 that it will disclose its third-quarter performance as per regulations [1]

Group 1 - The company, Fu'an Pharmaceutical, announced on September 26 that as of September 20, the number of shareholders reached 39,180 [1]

Group 1 - The company, Fu'an Pharmaceutical, has been established and developed in Chongqing for twenty years [1] - The company emphasizes its commitment to fulfilling social responsibilities and making contributions to society [1]

Group 1 - The company, Fu'an Pharmaceutical, announced on September 26 that it primarily produces chemical generic drugs [1] - The product range includes antibiotics, anti-tumor drugs, and specialty medications [1]

Group 1 - The company, Fu'an Pharmaceutical (300194), announced on September 26 that it is currently involved in a complex and lengthy civil litigation process in the United States [1] - The company is making efforts to expedite the litigation process while also respecting local legal procedures [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that its affiliated company has not yet obtained production approval, and the management is progressing with the construction project as per the situation [1] Company Summary - Fu'an Pharmaceutical's affiliated company is currently in the process of obtaining production approval, which has not yet been secured [1] - The management of the company is actively advancing the construction project based on the current circumstances [1]

Group 1 - The company, Fu'an Pharmaceutical (300194), announced on September 26 that it is currently involved in ongoing litigation and will pursue legal avenues to protect its interests [1] - The company's stock price fluctuations are influenced by multiple factors, and it will actively work to maintain its value [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that it has engaged in a series of mergers and acquisitions since its listing, continuously growing and expanding. The company aims to leverage its development platform and enhance management practices to achieve excellent results that satisfy investors [1] Group 1 - The company has conducted a series of mergers and acquisitions since its listing [1] - Fu'an Pharmaceutical is committed to utilizing its development platform effectively [1] - The company aims to improve its management practices to deliver satisfactory results to investors [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that it will disclose all R&D projects entering the registration process in its periodic reports and will provide interim disclosures for significant progress [1] Group 1 - The company will disclose relevant investments and matters that need to be reported through designated media [1]